Table 1 MCDPT and MVD expression, STLBS and STLAS levels as a function of clinicopathological characteristics in a series of 105 breast cancer patients
Variable | No. of patients | No. of tumours with high MCDPT * (%) | No. of tumours with high MVD ** (%) | No. of tumours with high STLBS *** (%) | No. of tumours with high STLAS **** (%) |
|---|---|---|---|---|---|
Age, years | Â | Â | Â | Â | Â |
Range 26-86 | 105 | Â | Â | Â | Â |
Median 58 | 105 | Â | Â | Â | Â |
< 58 years | 48 | 25 (53) | 29 (58) | 26 (55) | 27 (56) |
≥ 58 years | 57 | 33 (58) | 29 (51) | 31 (54) | 27 (48) |
Menopausal status | Â | Â | Â | Â | Â |
Premenopausal | 43 | 24 (55) | 21 (49) | 23 (53) | 25 (59) |
Postmenopausal | 62 | 36 (58) | 31 (50) | 32 (52) | 34 (55) |
Hystological type | Â | Â | Â | Â | Â |
Ductal | 78 | 41 (52) | 37 (47) | 38 (49) | 40 (51) |
Lobular | 27 | 14 (51) | 16 (58) | 13 (48) | 15 (55) |
Tumour size | Â | Â | Â | Â | Â |
pT1 | 49 | 26 (54) | 25 (55) | 27 (55) | 24 (49) |
pT2 | 36 | 16 (44) | 19 (52) | 18 (51) | 17 (47) |
pT3 | 20 | 12 (59) | 11 (54) | 10 (50) | 9 (47) |
Nodal status | Â | Â | Â | Â | Â |
pN0 | 44 | 19 (43) | 21 (48) | 20 (46) | 23 (52) |
pN1–2 | 61 | 29 (48) | 32 (53) | 33 (54) | 35 (58) |
Cytohistological grade | Â | Â | Â | Â | Â |
G1 | 37 | 19 (52) | 22 (60) | 21 (58) | 18 (48) |
G2 | 45 | 20 (44) | 23 (51) | 21 (47) | 22 (49) |
G3 | 23 | 12 (54) | 10 (45) | 11 (50) | 13 (56) |
Estrogen receptor status | Â | Â | Â | Â | Â |
Negative | 29 | 16 (55) | 17 (58) | 13 (46) | 14 (55) |
Positive | 76 | 37 (49) | 42 (55) | 36 (48) | 41 (54) |
Progesteron receptor status | Â | Â | Â | Â | Â |
Negative | 34 | 19 (55) | 16 (47) | 18 (53) | 17 (50) |
Positive | 71 | 36 (51) | 35 (49) | 39 (55) | 37 (52) |
c-erbB-2 status | Â | Â | Â | Â | Â |
Negative | 69 | 37 (54) | 33 (48) | 35 (51) | 37 (53) |
Positive | 36 | 22 (61) | 20 (55) | 19 (52) | 17 (48) |